Philip N. Newsome
0000-0001-6085-3652
Publication & Citation Trends
Publications
0 total
MASLD as a complication of obesity must include liver risk stratification
Cited by 2
Semantic Scholar
Abstracts from the CMHC 2025 Annual Conference
Cited by 0
Semantic Scholar
Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)
Cited by 4
Semantic Scholar
Erratum: Late breaking abstracts.
Cited by 0
Semantic Scholar
The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
Cited by 3
Semantic Scholar
P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis
Cited by 1
Semantic Scholar
Semaglutide-Treated Participants in the Phase 3 ESSENCE Trial (Part 1) Have Greater Concordance of Non-invasive Test Improvements Compared With Placebo
Cited by 0
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(316)
Liver Disease and Transplantation
(113)
Liver physiology and pathology
(84)
Diet, Metabolism, and Disease
(71)
Liver Diseases and Immunity
(53)
Affiliations
University of Southern California
National Health Service
Birmingham City University
Michael E. DeBakey VA Medical Center
Engineering and Physical Sciences Research Council